<DOC>
	<DOCNO>NCT01614964</DOCNO>
	<brief_summary>This initial efficacy study candidate antimalarial human subject uncomplicated malaria cause common important parasite Africa ( Plasmodium falciparum ) . This study enroll 66 adult Malian male uncomplicated P. falciparum malaria randomize treatment 1750 mg investigational drug ( AQ-13 ) mouth 3 day current standard treatment , 2 dos Coartem twice daily 3 day . The hypothesis underlie study AQ-13 similarly effective Coartem treatment uncomplicated P. falciparum malaria due chloroquine-susceptible chloroquine-resistant parasite . Funding Source - FDA Office Orphan Product Development ( OOPD ) .</brief_summary>
	<brief_title>Studies Candidate Aminoquinoline Antimalarial ( AQ-13 )</brief_title>
	<detailed_description>This initial efficacy study ( Phase 2 Proof Concept Study ) candidate antimalarial human subject uncomplicated malaria cause common important parasite Africa ( Plasmodium falciparum ) . This study enroll 66 adult Malian male uncomplicated P. falciparum malaria randomize treatment 1750 mg investigational drug ( AQ-13 ) mouth 3 day current standard treatment , 80 mg artemether 480 mg lumefantrine twice daily 3 day . The hypothesis underlie study AQ-13 similarly effective Coartem treatment uncomplicated P. falciparum malaria due chloroquine-susceptible chloroquine-resistant parasite .</detailed_description>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Inclusion Criteria 1 . Adult Malian male ≥ 18 year age , 2 . Uncomplicated malaria ≥ 2,000 asexual P. falciparum parasite per ul , 3 . Informed consent obtain sign . Exclusion Criteria 1 . Severe complicate malaria ( include temperature ≥ 40o C ) , 2 . ≥ 100,000 asexual parasite per ul blood , 3 . Anemia laboratory result ( malaria ) require treatment ( e.g. , Hb ≤ 7 gm/dL , K+ ≤ 3.5 millimolar ( mM ) , BP ≥ 140/90 ) , 4 . Seizures impair consciousness , 5 . Recent antimalarial treatment history ( within ≤ 2 week ) , 6 . Chronic medication ( include inducer Cytochrome P450 3A4 [ CYP3A4 ] activity rifampin nevirapine ) , 7 . Ventricular atrial arrhythmia , second third degree heart block screen ECG Holter recording , 8 . Infection plasmodial specie blood smear ( P. ovale , P. ovale , P. vivax ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>antimalarial ( antimalarial drug )</keyword>
	<keyword>chloroquine ( chloroquine-resistant )</keyword>
	<keyword>QT ( QTc ) interval</keyword>
</DOC>